IKT

Inhibikase is a clinical-stage pharma with zero commercial revenue and a widening loss — net income fell to -$48.3M in FY2025 from -$27.5M in FY2024, and operating income was -$52.0M. There is no product to value on earnings; the entire thesis rides on IKT-001, a prodrug of imatinib for pulmonary arterial hypertension, whose Phase 3 IMPROVE-PAH study the 10-K describes as only just 'initiated with the activation of a small number of sites and the recent commencement of patient pre-screening.' That is years from a data readout, and management explicitly states it is 'unable to predict when, if ever, material net cash inflows will commence.' This is a binary, single-asset bet, not a compounding business.

What keeps it out of 'avoid' is the balance sheet. The company raised heavily and ended FY2025 with $179M cash against just $8.30M of total liabilities and $173M of stockholders' equity — liabilities/equity of 0.05x and effectively no debt. Against operating cash burn of -$27.8M, that is a multi-year runway to reach clinical milestones without an imminent financing gun to the head. At $1.99 on ~132M shares (~$263M market cap), roughly two-thirds of the value is cash on hand, so the market is assigning only modest value to the pipeline itself.